Agriculture Adjuvants Market Size to Reach of US$ 6.2 Billion by 2032
Sales in the global agricultural adjuvants market are expected to grow at a steady 6.2% CAGR over the forecast period, reaching US$ 6.2 Bn by 2032. Increasing industrialization and colonization across ...
read more

Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to ...
read more
Freund's Adjuvant Market: Key Players and Strategies for Future Growth by 2023-2027
The MarketWatch News Department was not involved in the creation of this content. Mar 23, 2023 (The Expresswire) -- The "Freund's Adjuvant Market" research report is a comprehensive study that ...
read more
Agriculture Crop Adjuvant Market 2023 - Future Developments, Key Vendors, Regional Analysis, and Industry Scope by 2029
The drivers, restraints, opportunities, and challenges of the Agriculture Crop Adjuvant market are examined in detail after a detailed analysis of the microeconomic and macroeconomic factors affecting ...
read more

Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
Administering anti-PD-1 therapy has been shown to improve outcomes in the adjuvant setting but recent research has demonstrated benefit in the neoadjuvant setting due to the potential of activating ...
read more
CheckMate 274 Follow-Up Supports the Use of Adjuvant Immunotherapy in Bladder Cancer
Long-term data readouts from trials evaluating immunotherapeutic approaches in bladder cancer are changing the landscape, according to Lindsay Diamond, MSN, AGNP-C, AOCNP. Specifically, extended ...
read more
Neoadjuvant, Adjuvant Pembrolizumab Beneficial in Resectable Melanoma
FRIDAY, March 10, 2023 (HealthDay News) -- For patients with resectable stage III or IV melanoma, event-free survival is longer for those receiving neoadjuvant and adjuvant pembrolizumab compared ...
read more
Neoadjuvant, Adjuvant Pembrolizumab Beneficial in Resectable Melanoma
FRIDAY, March 10, 2023 (HealthDay News) — For patients with resectable stage III or IV melanoma, event-free survival is longer for those receiving neoadjuvant and adjuvant pembrolizumab compared with ...
read more
Husain Discusses Role of Osimertinib in Non–Small Cell Lung Cancer
During a Targeted Oncology™ Case-Based Roundtable™ event, Hatim Husain, MD, discussed data on targeted adjuvant therapy for non–small cell lung cancer.
read more
Roundtable Discussion: Pavlick and Participants Review Treatment and AE Management in Melanoma
During a Targeted Oncology™ Case-Based Roundtable™ event, Anna C. Pavlick, DO, MSc, MBA, BSN, discussed first-line therapy for a patient with metastatic melanoma.
read more
Related Blogs:
Adjuvant Targeted Melanoma Therapy Discussed Roundtable™ Oncology™ Neoadjuvant Roundtable™ Event Based Roundtable™ Targeted Oncology™